ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
This randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : sunitinib malate
- drug : sorafenib tosylate
- other : quality-of-life assessment
- other : placebo
- other : laboratory biomarker analysis
Phase: Phase 3
Ages Eligible For Study: